Effects of exogenous Fibroblast Growth Factor-21 on characteristic parameters related to energy metabolism in dairy cows

• Autorzy: Chen Y. , Wu Q. , Gao Y. , Zhang H. , Dong Z. , Li R. , Xu C.
• Języki publikacji: EN

Abstrakty

EN

Negative energy balance (NEB) is a common pathological foundation of fatty liver and ketosis. Liver and fat tissue are the major organs of lipid metabolism, which is also a key metabolic pathway that regulates NEB development during the perinatal period. Fibroblast growth factor-21 (FGF-21) is a protein hormone that plays an important role in adipose lipid metabolism and liver gluconeogenesis. Our aim was to investigate the effects of exogenous FGF-21 on characteristic parameters related to energy balance in dairy cows. Ten non-pregnant, non-lactating Holstein-Friesian dairy cows were randomly allocated into two groups. The interventions were exogenous FGF-21 injection group received 1 ug/kg BW (body weight) of recombinant bovine FGF-21 by intravenous injection, and control group received physiological saline injections by intravenous injection. In comparison to saline injections, intravenous injections of FGF-21 either increased or tended to increase concentrations of FGF-21 (p < 0.05), BHBA (p < 0.05), adiponectin, leptin and HDL-C. FGF-21 injections decreased or tended to decrease concentrations of insulin, glucose, glucagon (p < 0.05), ALT/GPT (p < 0.05), AST/GOT (p < 0.05), urate, creatinine (p < 0.05), BUN, triglyceride (p < 0.05), T-CHO and LDL-C (p < 0.05). The results indicate that FGF-21 has only negative effects on the metabolites and metabolic hormones related to NEB in serum of dairy cows, but it has more beneficial effects on prominent adipokines, liver function index, renal function index, lipoprotein profiles related to the pathological changes that occurred in NEB.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2019
• Tom: 75
• Numer: 12
• Opis fizyczny: p.738-743,fig.,ref.

Twórcy

autor

Chen Y.

• College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing High-tech Industrial Development Zone, 163319, Daqing China

autor

Wu Q.

• College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing High-tech Industrial Development Zone, 163319, Daqing China

autor

Gao Y.

• College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing High-tech Industrial Development Zone, 163319, Daqing China

autor

Zhang H.

• College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing High-tech Industrial Development Zone, 163319, Daqing China

autor

Dong Z.

• College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing High-tech Industrial Development Zone, 163319, Daqing China

autor

Li R.

• College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing High-tech Industrial Development Zone, 163319, Daqing China

autor

Xu C.

• College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing High-tech Industrial Development Zone, 163319, Daqing China

Bibliografia

• Chikhou F. H., Moloney A. P., Allen P., Quirke J. F., Austin F. H., Roche J. F.: Long-term effects of cimaterol in friesian steers: i. growth, feed efficiency, and selected carcass traits. J. Anim. Sci. 1993, 71, 906-913.
• Coskun T., Bina H. A., Schneider M. A., Dunbar J. D., Hu C. C., Chen Y., Moller D. E., Kharitonenkov A.: Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149, 6018-6027.
• Esteghamati A., Khandan A., Momeni A., Behdadnia A., Ghajar A., Nikdad M. S., Noshad S., Nakhjavani M., Afarideh M.: Circulating of levels fibroblast growth factor 21 in early-stage diabetic kidney disease. Irish J. Med. Sci. 2017, 186, 1-10.
• Kharitonenkov A., Larsen P.: FGF21 reloaded: challenges of a rapidly growing field.: Trends Endocrinol. Metabolism 2011, 22, 81-86.
• Kharitonenkov A., Shiyanova T. L., Koester A., Ford A. M., Micanovic R., Galbreath E. J., Sandusky G. E., Hammond L. J., Moyers J. S., Owens R. A., Gromada J., Brozinick J. T., Hawkins E. D., Wroblewski V. J., Li D. S., Mehrbod F., Jaskunas S. R., Shanafelt A. B.: Fgf-21 as a novel metabolic regulator.: J. Clin. Invest. 2015, 115, 1627-1635.
• Mraz M., Bartlova M., Lacinova Z., Michalsky D., Kasalicky M., Haluzikova D., Matoulek M., Dostalova I., Humenanska V., Haluzik M.: Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. 2009, 71, 369-375.
• Nishimura T., NakatakeY., Konishi M., Itoh N.: Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 2000, 1492, 203-206.
• Osorio J. S., Trevisi E., Ballou M. A.: Effect of the level of maternal energy intake prepartum on immunometabolic markers, polymorphonuclear leukocyte function, and neutrophil gene network expression in neonatal Holstein heifer calves. J. Dairy Sci. 2013, 96, 3573-3587.
• Schoenberg K. M., Giesy S. L., Harvatine K. J.: Plasma FGF-21 is elevated by the Intense lipid mobilization of lactation. Endorinology 2011, 152, 4652-4661.
• Shenoy V. K., Beaver K. M., Fisher F. M., Singhal G., Dushay J. R., Maratos-Flier E., Flier S. N.: Elevated Serum Fibroblast Growth Factor 21 in humans with Acute Pancreatitis. Plos One 2016, 11, e0164351.

Identyfikatory

DOI

10.21521/mw.6343